Priscila Mattar

Priscila Mattar is an endocrinologist and the vice-president of the medical area at Novo Nordisk, a leading pharmaceutical company. She has been actively involved in the discussion of diabetes and obesity treatments, particularly focusing on medications like Wegovy and Ozempic, which utilize the active ingredient semaglutida. In recent news, she highlighted the differences in dosing and efficacy between these medications, emphasizing the importance of proper medical supervision in their use for weight management and diabetes control.